Cardiac Steatosis in HIV-A Marker or Mediator of Disease?
Although people living with HIV (PLHIV) are approaching normal life expectancy, a limitation to achieving this goal is managing the higher prevalence of co-morbidities, including cardiovascular disease. Whilst ischaemic heart disease likely contributes to a large proportion of cardiac disease in the modern era of treatment, cardio-metabolic disease, including cardiac steatosis, akin to obesity-related heart disease, is also a possible mechanism of increased cardiac morbidity and mortality. HIV and other metabolic and inflammatory diseases affecting the heart, including obesity, share many cardio-metabolic abnormalities, with increased pericardial and myocardial fat content, in association with chronic systemic inflammatory changes and alterations in cardiac metabolism. Understanding the mechanisms of HIV-associated cardiac steatosis remains an important challenge, as managing the untreated metabolic and inflammatory precipitants may substantially improve cardiac outcomes for PLHIV.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1371/journal.pone.0160460
- https://doi.org//10.1016/j.amjcard.2015.10.030
- https://doi.org//10.1161/CIRCULATIONAHA.113.004574
- https://doi.org//10.1016/j.jchf.2015.05.003
- https://doi.org//10.1001/jamainternmed.2013.3728
- https://doi.org//10.1161/CIRCULATIONAHA.113.001719
- https://doi.org//10.1001/jamacardio.2017.0264
- https://doi.org//10.1093/cid/cix547
- https://doi.org//10.1016/j.jcmg.2014.12.019
- https://doi.org//10.1210/jc.2012-3190
- https://doi.org//10.1097/QAD.0000000000000116
- https://doi.org//10.1097/QAD.0b013e3283474b9f
- https://doi.org//10.1002/mrm.23011
- https://doi.org//10.1186/1475-2840-10-111